Dangerous Drugs Citation, commencement and extent 1 1 These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2018 and come into operation on 31st January 2018. 2 The Interpretation Act (Northern Ireland) 1954 shall apply to these Regulations as it applies to an Act of the Northern Ireland Assembly. 3 These Regulations extend to Northern Ireland. Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002 2 1 The Misuse of Drugs Regulations (Northern Ireland) 2002 are amended as follows. 2 In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)— a Before “Bufotenine” insert— Adinazolam (1-(8-Chloro-6-phenyl-4 H -[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)- N,N -dimethylmethanamine) N -Benzyl-ethylphenidate Bromazolam (8-bromo-1-methyl-6-phenyl-4 H -[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) b after “Cathinone” insert— 4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one) Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine) ; c after “Concentrate of poppy-straw” insert— Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine) 3,4-Dichloroethylphenidate 3,4-Dichloromethylphenidate (3,4-DCMP) Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1.3-dihydro-2H-1,4-benzodiazepin-2-one) ; d after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert— Ethylnaphthidate Ethylphenidate ; e after “Eticyclidine” insert— Etizolam ; f after “Etryptamine” insert— Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one) Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine) 4-Fluoroethylphenidate 4-Fluorometylphenidate Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one) ; g after “9-Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10, 10a- tetrahydrobenzo[c]chromen-1-ol” insert— 3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one) Isopropylphenidate (IPP or IPPD) ; h after “Lysergide and other N-alkyl derivatives of lysergamide” insert— Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one) ; i after “Methcathinone” insert— 4-Methylmethylphenidate Methylmorphenate Methylnaphthidate (HDMP-28) N -methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA) Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine) Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one) Nitrazolam (1-Methyl-8-nitro-6-phenyl-4 H -[1,2,4] triazolo[4,3-a][1,4]benzodiazepine) Propylphenidate ; j after “Psilocin” insert— Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4 H -[1,2,4]triazolo[4,3-a][1,4] benzodiazepine) ; k after “3,4-dichloro- N -[[1-(dimethylamino)cyclohexy]methyl]benzamide (AH-7921)” insert— 3,4-dichloro- N -[2-dimethylamino)cyclohexyl]- N -methylbenzamide (U-47,700) ; 3 After paragraph 1(c) of Schedule 1, insert — ca any compound (not being clonitazene, etonitazene, acemetacin, atorvastatin, bazedoxifene, indometacin, losartan, olmesartan, proglumetacin, telmisartan, viminol, zafirlukast or a compound for the time being specified in sub-paragraph (c) above) structurally related to 1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four substructures, that is to say the indole ring, the pentyl substituent, the methanone linking group and the naphthyl ring, are linked together in a similar manner, whether or not any of the sub-structures have been modified, and whether or not substituted in any of the linked sub-structures with one or more univalent substituents and, where any of the sub-structures have been modified, the modifications of the sub-structures are limited to any of the following, that is to say— i replacement of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole, benzimidazole, pyrrolo[2,3-b]pyridine, pyrrolo[3,2-c]pyridine orpyrazolo[3,4-b]pyridine; ii replacement of the pentyl substituent with alkyl, alkenyl, benzyl,cycloalkylmethyl, cycloalkylethyl, ( N -methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl or (tetrahydropyran-4-yl)methyl; iii replacement of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene bridge or methine group; iv replacement of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl, cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl, 1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1-amino-1-oxopropan-2-yl, 1-hydroxy-1-oxopropan-2-yl, piperidinyl, morpholinyl, pyrrolidinyl, tetrahydropyranyl or piperazinyl. 4 In paragraph 1 of Part 2 of Schedule 4 (which specifies Controlled Drugs Excepted from the Prohibition on Possession; Excluded from the Application of Offences Arising from the Prohibition on Importation and Exportation when Carried Out in Person for Administration to That Person; and Subject to the Requirements of Regulations 22, 23, 26 and 27), after “Desoxymethyltestosterone” insert— Dienedione (estra-4, 9-diene-3, 17-dione) . Sealed with the Official Seal of the Department of Health on 10th January 2018 Dr Mark Timoney A senior officer of the Department of Health